[1] Global Initiative for Chronic Obstructive Lung Disease.2022 GOLD Report.Global strategy for the diagnosis,management and prevention of COPD[EB/OL].2022 [2022-11-02].https://goldcopd.org/2022-gold-reports-2/.
[2] 尹晓娇,陈宏.从临床角度解读肺癌合并慢性阻塞性肺疾病[J].现代医学,2017,45(10):1525-1528.
[3] RODRIGUES S O,CUNHA C M C D,SOARES G M V,et al.Mechanisms,pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease[J].Pharmaceuticals(Basel),2021,14(10):979.
[4] MANDEL J,CASARI M,STEPANYAN M,et al.Beyond hemostasis:platelet innate immune interactions and thromboinflammation[J].Int J Mol Sci,2022,23(7):3868.
[5] WIENKAMP A K,ERPENBECK L,ROSSAINT J.Platelets in the NETworks interweaving inflammation and thrombosis[J].Front Immunol,2022,13:953129.
[6] MALLAH H,BALL S,SEKHON J,et al.Platelets in chronic obstructive pulmonary disease:an update on pathophysiology and implications for antiplatelet therapy[J].Respir Med,2020,171:106098.
[7] ZINELLU A,PALIOGIANNIS P,SOTGIU E,et al.Plateletcount and platelet indices in patients with stable and acute exacerbation of chronic obstructive pulmonary disease:a systematic review and Meta-analysis[J].COPD,2021，18(2),231-245.
[8] FAWZY A,PUTCHA N,AARON C P,et al.Aspirin use and respiratory morbidity in COPD:a propensity score-matched analysis in subpopulations and intermediate outcome measures in COPD study[J].Chest,2019,155(3):519-527.
[9] LEFRANCAIS E,ORTIZ-MUÑOZ G,Caudrillier A,et al.The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J].Nature,2017,544(7648):105-109.
[10] LEFRANCAIS E,LOONEY M R.Platelet biogenesis in the lung circulation[J].Physiology(Bethesda),2019,34(6):392-401.
[11] HUANG D Y,WANG G M,KE Z R,et al.Megakaryocytes in pulmonary diseases[J].Life Sci,2022,301:120602.
[12] VAN DER MEIJDEN P E J,HEEMSKERK J W M.Platelet biology and functions:new concepts and clinical perspectives[J].Nat Rev Cardiol,2019,16(3):166-179.
[13] OUZEGDOUH Y,CAPRON C,BAUER T,et al.The physical and cellular conditions of the human pulmonary circulation enable thrombopoiesis[J].Exp Hematol,2018,63:22-27.e3.
[14] PARISER D N,HILT Z T,TURE S K,et al.Lung megakaryocytes are immune modulatory cells[J].J Clin Invest,2021,131(1):e137377.
[15] CHANG Y P,CHEN Y M,CHANG Y C,et al.Association of baseline parameters with year 0 and year 1 acute exacerbations in male patients with chronic obstructive pulmonary disease[J].Int J Immunopathol Pharmacol,2022,36:3946320221099073.
[16] LIU M,HU R,JIANG X,et al.Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia[J].J Clin Lab Anal,2021,35(4):e23733.
[17] CHEN L,XU W,CHEN J,et al.Evaluating the clinical role of fibrinogen,D-dimer,mean platelet volume in patients with acute exacerbation of COPD[J].Heart Lung,2022,57:54-58.
[18] ZHANG M,LI Y,ZHANG J,et al.Mean platelet volume is elevated in exacerbated and convalescent COPD patients[J].Clin Chim Acta,2015,451(Pt B):227-231.
[19] BIALAS A J,PEDONE C,PIOTROWSKI W J,et al.Platelet distribution width as a prognostic factor in patients with COPD-pilot study[J].Int J Chron Obstruct Pulmon Dis,2017,12:2261-2267.
[20] EMAMI ARDESTANI M,ALAVI NAEINI N.Evaluation of the prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute exacerbation of chronic obstructive pulmonary disease[J].J Res Med Sci,2022,27:50.
[21] ERASLAN DOGANAY G,CIRIK M O.Are neutrophil-lymphocyte,platelet-lymphocyte,and monocyte-lymphocyte ratios prognostic indicators in patients with chronic obstructive pulmonary disease in intensive care units?[J].Cureus,2022,14(3):e23499.
[22] LUO Z,ZHANG W,CHEN L,et al.Prognostic value of neutrophil:lymphocyte and platelet:lymphocyte ratios for 28-day mortality of patients with AECOPD[J].Int J Gen Med,2021,14:2839-2848.
[23] LIU X,GE H,FENG X,et al.The combination of hemogram indexes to predict exacerbation in stable chronic obstructive pulmonary disease[J].Front Med(Lausanne),2020,7:572435.
[24] ROBERT L,LABAT-ROBERT J.Platelets,micro-particles and elastase.A review with extrapolation to the mechanism of generation and bio-pathology of platelet fragments[J].Pathol Oncol Res,2017,23(2):455-458.
[25] MUÑOZ-ESQUERRE M,FERREIRO J L,HUERTAS D,et al.Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients[J].Int J Chron Obstruct Pulmon Dis,2017,13:141-148.
[26] LONKY S A,WOHL H.Stimulation of human leukocyte elastase by platelet factor 4.Physiologic,morphologic,and biochemical effects on hamster lungs in vitro[J].J Clin Invest,1981,67:817-826.
[27] MIDDLETON E A,WEYRICH A S,ZIMMERMAN G A.Platelets in pulmonary immune responses and inflammatory lung diseases[J].Physiol Rev，2016，96(4):1211-1259.
[28] SU Y,HAN W,KOVACS-KASA A,et al.HDAC6 activates ERK in airway and pulmonary vascular remodeling of chronic obstructive pulmonary disease[J].Am J Respir Cell Mol Biol,2021,65(6):603-614.
[29] 梁乐诗,莫环琦,张弋,等.血小板与慢性阻塞性肺疾病相关研究进展[J].中华结核和呼吸杂志,2022,10:1050-1054.
[30] RIGG R A,HEALY L D,CHU T T,et al.Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions[J].Platelets,2019,30(1):126-135.
[31] CHAURASIA S N,KUSHWAHA G,KULKARNI P P,et al.Platelet HIF-2α promotes thrombogenicity through PAI-1 synthesis and extracellular vesicle release[J].Haematologica,2019,104(12):2482-2492.
[32] MACLAY J D,MCALLISTER D A,JOHNSTON S,et al.Increased platelet activation in patients with stable and acute exacerbation of COPD[J].Thorax,2011,66(9):769-774.
[33] SCHROTTMAIER W C,MUSSBACHER M,SALZMANN M,et al.PI3K isoform signalling in platelets[J].Curr Top Microbiol Immunol,2022,436:255-285.
[34] JOHANSSON D,SHANNON O,RASMUSSEN M.Platelet and neutrophil responses to Gram positive pathogens in patients with bacteremic infection[J].PLoS One,2011,6(11):e26928.
[35] NGAMSRI K C,PUTRI R A,JANS C,et al.CXCR4 and CXCR7 inhibition ameliorates the formation of platelet-neutrophil complexes and neutrophil extracellular traps through Adora2b signaling[J].Int J Mol Sci,2021,22(24):13576.
[36] COOPERSMITH C M,DE B D,DEUTSCHMAN C S,et al.Surviving sepsis campaign:research priorities for sepsis and septic shock[J].Crit.Care Med,2018,46:1334-1356.
[37] KONRAD F M,MEICHSSNER N,BURY A,et al.Inhibition of SDF-1 receptors CXCR4 and CXCR7 attenuates acute pulmonary inflammation via the adenosine A2B-receptor on blood cells[J].Cell Death Dis,2017,8:e2832.
[38] SIN D D.The devastating power of platelets in COPD exacerbations:can aspirin save lives in COPD?[J].Thorax,2014,69(7):603-604.
[39] PATRONO C.Fifty years with aspirin and platelets[J].Br J Pharmacol,2023,180(1):25-43.
[40] MONTUSCHI P,MACAGNO F,PARENTE P,et al.Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD[J].Thorax,2005,60(10):827-833.
[41] RAMOS-NINO M E,MACLEAN C D,LITTENBERG B.Association between the prevalence of obstructive lung disease and the use of aspirin in a diabetic population[J].Interv Pulmonol(Middlet),2022,1(1):5-10.
[42] AARON C P,SCHWARTZ J E,HOFFMAN E A,et al.A longitudinal cohort study of aspirin use and progression of emphysema-like lung characteristics on CT imaging:the MESA lung study[J].Chest,2018,154(1):41-50,23
[43] PAVASINI R,BISCAGLIA S,D'ASCENZO F,et al.Antiplatelet treatment reduces all-cause mortality in COPD patients:a systematic review and Meta-analysis[J].COPD,2016,13(4):509-514.
[44] GOTO T,FARIDI M K,CAMARGO C A,et al.The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease:a retrospective cohort study[J].NPJ Prim Care Respir Med,2018,28(1):7.
[45] HARRISON M T,SHORT P,WILLIAMSON P A,et al.Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease:a role for antiplatelet therapy?[J].Thorax,2014,69(7):609615.
[46] BAKSHI A,SUISSA S.Effectiveness of aspirin in COPD:biases in the observational studies[J].COPD,2021,18(4):449-455.
[47] YU S Y,IP M S,LI X,et al.Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong:a cohort study[J].PLoS Med,2022,19(1):e1003880.
[48] KUNADIAN V,WILSON N,STOCKEN D D,et al.Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease:a randomised controlled proof-of-concept trial[J].ERJ Open Res,2019,5(3):00110-2019. |
